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Summary.-In a clinical investigation of postoperative survival after primary
surgery for stomach cancer, 390 patients were registered since 1974. The potential
prognostic parameters examined within the first days of hospitalization for primary
resection included age ofthe patients, operability, tumour extension (TNM classifica-
tion) and tumour stages I-IV (UICC). Statistical treatment of the data revealed that
each of the clinical parameters covers critical ranges associated with highly signifi-
cant differences in patient survival. The preoperative serum CEA concentration
exhibited prognostic significance in addition to the criteria of operability and tumour
extension. In selected subgroups of patients with distinct resectability and tumour
extension, ranges of preoperative CEA concentration could be specified which were
associated with statistically significant differences in the patient survival. The results
indicate that the preoperative serum CEA level can be an independent prognostic
parameter in stomach cancer.
THE increasing number of studies on
the correlation ofpreoperative CEA serum
level with disease recurrence or patient
survival indicates that the preoperative
serum CEA concentration has prognostic
value in various types of malignant
disease. A positive correlation with survi-
val was reported for patients with lung
cancer (Concannon et al., 1978; Vincent
et al., 1979; Stokes et al., 1980; Ford et al.,
1981) and colorectal cancer (Kohler et al.,
1980; Staab et al., 1981), a positive
correlation with disease recurrence was
reported for patients with resected colorec-
tal cancer (Wanebo et al., 1978; Evans
et al., 1978; Goslin et al., 1980) and
cervix cancer (Kjorstad & 0rjasaeter,
1982). The prognostic significance of the
preoperative CEA level was still evident
when selected subgroups of patients with
distinct resectability and tumour exten-
sion were examined (Staab et al., 1981)
thus representing a prognostic marker
independent of resectability and clinical
staging. These findings open up the
possibility of including preoperative
measurements of serum CEA concentra-
tion in the set of prognostic parameters,
such as resectability and tumour exten-
sion, which can be established within a
few days, during hospitalization of
patients for primary treatment.
Our present report investigates whether
preoperative serum CEA levels also repre-
sents an independent prognostic para-
meter in stomach cancer, since in this
type of cancer not only the frequency of
CEA+ cases but also the mean serum CEA
levels in these patients were found to be
distinctly lower than in lung or colorectal
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cancer. Part of a long-term follow-up
of patients with stomach cancer, started
by us in 1974, was set up to examine the
prognostic value of preoperative serum
levels of CEA as a molecular marker, in
comparison to clinical staging and re-
sectability. Special attention has been
paid to the question whether the prog-
nostic information from preoperative CEA
levels is entirely linked to the prog-
nostic information from clinical staging
and resectability. Preliminary results
(Staab et al., 1980) indicated a potential
gain in prognostic information when the
preoperative CEA level was considered in
addition to the clinical parameters. The
data collected from 390 patients with
stomach cancer during the years 1974-81
are now used for a statistical analysis.
The statistical treatment of data was
based on the observed survival, and
considered the following subgroups of the
main prognostic parameters: (a) resect-
ability, (b) tumour extension, (c) age, and
(d) preoperative CEA levels, as well as
subgroups with selected combinations of
up to three of those parameters. The
results demonstrate that the preoperative
serum CEA level can be used as an addi-
tional prognostic parameter in stomach
cancer.
PATIENTS AND METHODS
Patients.-390 patients (male: female=
2.22) were registered for primary resection
of carcinoma of the stomach in the Chirur-
gische Klinik Stuttgart-Bad Cannstatt since
1974. In all cases the resected tumours and
biopsies were characterized histologically.
Blood samples were taken the first or second
day of hospitalization before surgery. For
the characterization of the extent of the
tumour we used the 1978 TNM classification
of the International Union Against Cancer
(UICC) or in cases oflow numbers ofpatients
in TNM subgroups we used tumour Stages
I-IV, also recommended by UICC (1978).
Resectability of tumours was classified by
the surgeon according to the categories
'radical resection', 'palliative resection', and
'nonresectable', as judged from the operative
findings and the pathologist's report. 'Non-
resectable' means that surgery was limited
to explorative laparotomy and biopsies only.
All patients were registered for a post-
operative follow-up, which included routine
serum CEA determinations and catamnestic
examinations every 2-3 months. A computer-
ized call-in program was developed to keep
in contact with the patients. When death was
not registered in the clinic, confirmation was
obtained from the family doctor, from
relatives of the patients or from the local
community administrations. Patients who
underwent second-look surgery (14) or re-
ceived post-operative chemotherapy (6) were
excluded from the study.
CEA assay.-Serum CEA concentrations
were assayed with the CEA-Roche-RIA
test kit (Hoffman-La Roche, Basel, Switzer-
land) using only the indirect method. When
CEA concentrations were >20 ,tg/l the sera
were prediluted with adequate normal serum.
Possible variations of the reagents of the
commercial CEA-RIA test kit were con-
trolled on the basis of our own internal CEA
standards throughout the years. The inter-
assay standard deviation for CEA determina-
tion at concentrations of 5-7 ,tg CEA/l
serum was +0-7 ,tg CEA/l, and at concentra-
tions of 10-5 ,ug CEA/I +0-8 jug CEA/I.
Statistical analysis.-Survival curves were
computed by the life-table method recom-
mended by Peto et al. (1976, 1977) and the
American Joint Committee for Cancer Stag-
ing (1977). To determine the statistical
significance of differences between the esti-
mated proportions of observed survival in
2 different groups of patients the log-rank
test (Peto & Peto, 1972) was used. Deaths
registered during the first 30 days after
surgery were not considered tumour depen-
dent, and were excluded from survival
curves and significance calculations.
Statistical treatment of potential prog-
nostic data was based on the survival after
primary surgical treatment of 390 patients
with carcinomas of the stomach. In a first
step, computations of observed survival
curves were performed with subgroups of
patients based on variable criteria of single
prognostic parameters. To test whether the
prognostic parameters provide independent
information, in a second step ofcomputations
the subgroups were defined by the criteria of
a combination of 2 prognostic parameters
and, in a third step, combinations of 3
prognostic parameters were used.
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RESULTS
Prognostic criteria based on single para-
meters
In the first set of subgroups the signi-
ficance of differences in observed survival
curves based on all registered patients
(n= 390) was examined for various ranges
a: Total patients: preoperative C
10
:XK~~~~~~~21
\ 10
c:Total patients: operability
100 S
of age, preoperative CEA concentration,
classes of resectability and tumour ex-
tension. For the characterization of the
prognostic value of tumour extension, we
used TNM subdivisions as well as sub-
divisions according to tumour stages I-IV
(International Union Against Cancer,
1978) which also include criteria of
days after operation
FIa. 1.-Survival curves for patients grouped according to various prognostic criteria: r= radical
surgery, p=palliative, nr=non-resectable. The dotted curve represents the survival for all patients.
The statistical significance is listed in Table I.
I
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TABLE I.-Statistical significance (P) of differences between the survival curves of the
related subgroups ofpatients shown in Fig. 1. Subdivision ofpatients is based on single
prognostic parameters: age, preoperative CEA levels, tumour extension (TNM clasi-
fication), operability and tumour stages I-IV. n0=total number ofpatients registeredin
each subgroup; np=number ofpatients dying within 30 days ofsurgery. P inparentheses
refers to computations including np patients
Subgroups
Age (years)
Preoperative CEA (,ug/l)
Tumour extension (TNM)
Operability
radical resection
palliative
nonresectable
Tumour stage (UICC)
I+II
III
IV
I
II
<70
>70
0-2
>2
0-4
>4
0-2
2-10
>10
T1-3NoMo
T4NoMo
T4N1-3Mo
Tl-4No-3MI
T1-3NoMo
TI-3NI-3Mo
T1-2NoMo
T3NoMo
Age ratio
< 70/> 70
0 78
0*90
0 71
0-81
0-71
0 90
0-64
0 97
0-72
0-96
0*57
1 27
0-72
0 77
1-36
0 45
0-82
0 63
1 -20
0-72
0-78
0-78
1 *00
0-67
resectability (i.e. resectable tumours in
Stages I-III and tumours not radically
resectable or nonresectable in Stage IV).
Computation of the observed survival
curves of patients in various age ranges
revealed no significant differences between
subgroups < 60 years, 60-70 years and
> 70 years. The survival curves computed
for subgroups with different ranges of
the preoperative CEA levels, tumour
extension, operability and tumour stage
are given in Fig. 1. In Table I the statis-
tical significance (P) is listed together
with the registered number of patients in
each subgroup (no) and the number of
cases of postoperative death occurring
within 30 days after surgery (np), which
were excluded in the first set of compu-
tations of survival curves and statistical
significance but included into the second
no
171
219
154
236
267
123
154
177
59
81
49
133
75
81
37
33
48
147
168
75
81
82
212
16
65
np
14
31
19
26
30
15
19
16
10
9
1
22
10
9
2
1
8
8
27
10
9
2
33
0
9
p
0-25 (0-13)
0*004 (0.008)
0 008 (0*005)
0*07 (0.12)
<0-001 (<0.001)
0*005 (0-12)
<0001 (<0.001)
0*04 (0.09)
0-002 (0.04)
0 7 (0-14)
<0 001 (O 001)
<0-001 (<0-001)
0-002 (0.05)
<0-001 (<0.001)
0*5 (0.5)
set of significance calculations (P values
given in parentheses). In addition, for
all subgroups of patients the age ratio
< 70/ > 70 years was listed, to give infor-
mation on the age distribution in each
subgroup.
Examination of the observed survival
curves of subgroups of patients with
various arbitrary ranges of preoperative
serum CEA levels (Fig. la) revealed
significant differences in survival between
patients with CEA ranges of 0-2,ug/l and
>2,ug/l, 0-4 and > 4, 2-10 and > 10, and
differences close to significance between
patients with CEA ranges of 0-2 and
2-10 (Table I). Inclusion in the computa-
tions of patients dying within 30 days
after surgery did not essentially change
the significance of differences in survival.
Some ofthe corresponding survival curves
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were omitted from Fig. la for better
clarity.
The prognostic criteria of resectability
(r=radical resection, p=palliative re-
section and nr=nonresectable) yielded
survival curves (Fig. lc) showing highly
significant differences (Table I). Patients
with nonresectable tumours had such a
poor prognosis that further computations
for this group, examining additional
prognostic parameters were omitted.
Computations of the survival curves
based on tumour extension (TNM classi-
fication) could be made with a total of
only 375 patients, since the staging of
of 15 patients was incomplete. The
survival curves of the subgroups are
given in Fig. lb. No significant differences
were obtained between patients with
Tl-2NoMo tumours and those with T3-
NoMo tumours (Table I) but the survival
a: Patients with radically resected tumo
preoperative CEA Ogl/0)
100
.00
50-
curves were significantly different between
patients with Tl-3NoMo tumours and
those with T4NoMo tumours (Table I).
In all subgroups of patients with lymph-
node metastasis (i.e. Tl-3N1-3Mo or
T4Nl-3Mo) significantly worse survival
was observed than for patients with
Tl-3NoMo or T4NoMo tumours. A further
significant decrease in survival was found
on comparing patients with distant meta-
stasis with those with T4Nl-3Mo tumours,
though the latter group contained twice
the proportion of patients > 70 years
(Table I). Computations including patients
dying within 30 days of surgery yielded
partial changes in the significance of
differences in survival. In two cases
(i.e., between patients with Tl-3NoMo
and T4NoMo tumours and between
patients with T4Nl-3Mo and Tl-4No-3M1
tumours) the differences in survival were
days after operation
FIG. 2. Survival curves for subgroups of patients with radically resected tumours (a) or Stage III
tumours (b) according to ranges of preoperative serum CEA concentration. The dotted curves
represent the survival for all patients in (a) or (b). The total number of patients in each subgroup
and the statistical significance is listed in Table II.
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TABLE II.-Statistical significance (P) of differences between the survival curves of the
related subgroups of patients shown in Fig. 2. Subdivision of patients is based on a
combination of different categories of resectability or tumour stages and ranges of pre-
operative serum CEA concentration. nO and np as in Table I
Subgroups
Radical resection
Palliative resection
Stages 1+II
Stage Ilf
Stage IV
co h._
D
Preoperative CEA
(Gg/l)
0-2
>2
0-4
>4
0-5
> 5
0-10
> 10
0-4
>4
0-2
>2
0-4
>4
0-4
4-10
>10
days after operation
FIG. 3. Survival curves for subgroups of patients with radically resected TI-3N1-3Mo (a) or T4No-
3Mo tumours (b). Subdivisions are based on ranges of preoperative concentrations of serum CEA.
The dotted lines represent the survival of all patients in (a) or (b). Numerical data in Table III.
Age ratio
< 70/ > 70
1.09
0-63
1 .00
0 40
0-58
0 70
0-60
0-69
0-80
0 40
0-94
0-66
1*00
0-27
0 75
0-88
0-81
n7o
69
78
112
35
122
46
141
27
66
15
34
48
63
19
133
32
47
np
5
3
6
2
20
7
22
5
7
2
1
1
1
1
20
2
10
p
0 1 (0 26)
0-02 (0 04)
0 4 (0 26)
0 -16 (0 32)
0 8 (0 89)
0-1 (0.09)
0-02 (0-003)
0 - 14 (0 06)
0 05 (0 007)
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TABLE III.-Statistical significance (P) of differences between the survival curves of the
related subgroups of patients shown in Fig. 3. Subdivision of patients is based on
combination of 3 prognostic parameters: patients with radical resections are listed
according to TNM classification and preoperative CEA ranges. nO and np as in Table I
Preoperative CEA
(tg/l)
0-2
>2
0-4
>4
0-2
>2
0-4
>4
0-2
>2
0-4
>4
no longer significant (Table I, compare P
values in parentheses). When the prog-
nostic value of tumour extension was
examined on the basis of Stages I-IV,
the survival curves (Fig. Id) were signifi-
cantly different between Stage I +11
patients and Stage III patients, and
between Stage III and Stage IV patients
(Table I) which is compatible with the
results from computations according to
TNM and resectability.
Prognostic criteria based on combinations of
2-3 parameters
To decide whether some ofthe ranges of
the preoperative serum CEA level are
prognostic markers, independent ofresect-
ability, computations of the observed
survival curves were performed for
patients with radically and palliatively
resected tumours, using various ranges
of preoperative serum CEA concentration
as additional criteria. In the groups of
patients with palliatively resected tum-
ours, no subgroups with distinct pre-
operative CEA ranges exhibited signifi-
cant differences in survival. Examples are
given for CEA ranges 0-5/> 5 and 0-10/
> 10ug CEA/I in Table II. However,
computations of survival curves for sub-
groups of patients with radically resected
tumours, based on various preoperative
CEA ranges (Fig. 2a) revealed significant
differences between patients with 0-4-
,ugCEA/l and > 4,gCEA/l, but not with
ranges of 0-2 and > 2 (Table II). Thus in
this subgroup, the CEA ranges 0-4 and
> 4 ,ug/l provide additional prognostic
information.
The prognostic information of tumour
extension based on Stage I-IV criteria
(Fig. Id, Table I) already included
resectability as a second prognostic para-
meter discriminating radically resectable
TINoMo (Stage I), T2-3NoMo (Stage II),
TI-3NI-3Mo and T4No-3Mo tumours
(Stage III), and not radically resectable
or nonresectable TI-3N3Mo, T4No-3Mo
and TI-4No-3MI tumours (Stage IV).
When the groups of patients with dis-
tinct tumour stages were subdivided
according to ranges of the preoperative
CEA level, we found no significant
differences in observed survival for the
CEA subgroups of patients with Stage
(I+11) tumours (Table II) but survival
was significantly different for patients
with Stage III tumours and CEA ranges
of 0-4 and >4 ,ug/l (Fig. 2b, Table II)
and for patients with Stage IV tumours
and CEA ranges of 4-10 and > 10 ,g/l
(Table II).
Final confirmation that the preopera-
tive serum CEA level can serve as an
independent prognostic parameter, was
obtained from computations of survival
curves for subgroups of patients with
radically resected tumours of distinct
Subgroup
TI-3NoMo
TI-3NI-3Mo
T4No-3Mo
np P
Age ratio
< 70/ > 70
1*15
0-46
0-85
0 50
0-80
0 39
0- 73
0-25
1*14
0-82
1 25
0-25
no
43
35
63
15
18
18
26
10
15
31
36
10
5
3
6
2
1
1
1
1
0
0
0
0
0-8 (0 95)
0 9(0 94)
0*06 (0*07)
0-02 (0.02)
0*03 (0*03)
0*07 (0*07)
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tumour extension (TNM classification).
Such patients were subdivided into sub-
groups with the following tumour exten-
sions: TI-3NoMo, TI-3NI-3Mo and
T4No-3Mo. Tl-2NoMo and T3NoMo tum-
our classes were combined, since the
corresponding groups of patients showed
no significantly different survival (Table
I). Patients with distant metastasis were
not found among patients with radical
resections, and patients who had under-
gone palliative surgery showed no signi-
ficantly different survival according to
preoperative CEA levels (Table II).
Computations of observed survival cur-
ves of patients with radically resected
tumours and distinct tumour extension
were based on the preoperative CEA
ranges 0-4 and > 4 /tg/l or 0-2 and > 2
,g/l. The resulting curves of the first
2 subgroups are shown in Fig. 3. In the
group of patients with radically resected
T1-3NoMo tumours, no difference in
survival between any CEA subgroups was
found (Table III). For the ranges of
preoperative CEA 0-4 and >4 ,tg/l, a
significant difference was obtained for
patients with resected T1-3N1-3Mo tum-
ours (P=0-02) and a difference close to
significance for patients with resected
T4No-3Mo tumours (P=0.07). These dif-
ferences became less (Tl-3NI-3Mo) or
more (T4No-3Mo) significant when CEA
ranges of 0-2 and > 2 ,tg/l were con-
sidered (Table III). Thus the prognostic
information of distinct ranges of the
preoperative CEA concentration is not
linked to radical resection and tumour
extension in the classes T1-3NI-3Mo and
T4No-3Mo.
DISCUSSION
The clinical prognostic criteria of
stomach cancer, available shortly after
hospitalization for surgery, are generally
based on the criteria of resectability,
tumour extension, age and general con-
dition of patients. The reliability of these
prognostic parameters is now compared
with the prognostic information obtained
from the preoperative serum CEA levels
of the patients. The data were collected
during a long-term follow-up of 390
patients with stomach cancer since 1974.
Computation of the survival curves of
various subgroups of patients confirmed
that resectability (with the criteria "radi-
cal resection", "palliative resection" and
"nonresectable") is a highly significant
prognostic parameter. Furthermore, it
was confirmed that tumour extension
(TNM classification) also had prognostic
value, though no prognostic difference
was found between the classes T1-2NoMo
and T3NoMo. However, patients with
such tumours showed significantly better
survival than patients with T4NoMo
tumours. With lymph-node metastasis
(N1-3) prognosis became significantly
poorer in the subgroups of patients with
T1-3 tumours, as well as in the T4 sub-
groups. Distant metastasis (M= 1) cor-
related with a still poorer prognosis.
Computations based on 2 clinical para-
meters such as resectability and tumour
extension (Stages I-IV) also revealed
significant differences in survival which
correlated well with the differences be-
tween TNM subgroups. These findings
refer only to calculations based on survival
excluding the patients dying less than
30 days after surgery, whose death might
not be directly tumour-dependent but
involve post-surgery complications. When
these patients were included, some dif-
ferences in survival of patients with
distinct tumour extension became less
or no more significant (Table I). The
prognostic significance of the age classes
< 70 and > 70 years, recently reported
by us in colorectal-cancer patients (Staab
et al., 1981) was not found in the present
group of stomach-cancer patients.
Preoperative circulating CEA provides
additional prognostic information in sto-
mach cancer. Patients with various ranges
ofpreoperative CEA concentration showed
highly significant differences in survival
(Table I). Computations of survival of
subgroups obtained by combining various
ranges of preoperative CEA concentration
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ranges of preoperative serum CEA
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FIG. 4.-Differences in the distribution of
390 stomach-cancer patients and 563 colo-
rectal-cancer patients over distinct ranges
of preoperative CEA levels.
with clinical parameters revealed an addi-
tional prognostic value of circulating
CEA for patients with radical resection,
distinct tumour extension (TNM) and
Stages III+IV tumours. Stomach-cancer
patients with TI-3NoMo tumours, how-
ever, or Stages I+11showed no differences
in survival when subdivided into groups
with ranges 0-2, 0-3, 0-4 ug/l and
> 2, > 3, > 4 jg CEA/l, respectively. These
findings indicated a difference from
patients with TI-2NoMo and T3NoMo
colorectal cancer, who showed a signifi-
cantly different survival when groups with
different preoperative CEA ranges were
compared (Staab et al., 1981). The reason
forthisdiscrepancymightbepartlybecause
stomach-cancer patients generally develop
distinctly lower levels of circulating CEA
than colorectal-cancer patients. This be-
comes evident when the distribution of
stomach cancer patients covering distinct
ranges of the preoperative CEA levels is
compared with that of colorectal cancer
patients (Fig. 4). In the CEA range up to
3 p.g/l, patients with stomach cancer had
a higher frequency, whereas in the ranges
> 3 jug/l patients with colorectal cancer
had higher frequencies. The partial differ-
ences in prognostic value might also
derive from the generally poorer prog-
nosis of stomach-cancer patients than
colorectal-cancer patients. Five years after
primary treatment only 30% of our
stomach cancer patients (n= 390) were
still alive, whereas more than 50% of our
colorectal cancer patients (n= 563) had
survived (Staab et al., 1981).
Because the preoperative CEA level is
not linked prognostically to resectability
or tumour extension, it provides addi-
tional prognostic information. However,
a possible linkage between the preopera-
tive CEA level and histological type or
grading has not yet been evaluated. The
corresponding investigations are proceed-
ing.
The prognostic value of distinct ranges
of preoperative CEA should facilitate the
management of stomach-cancer patients
for adjuvant postoperative treatment. A
generalization from our results would
have to be based on our methods. Other
CEA test systems would be expected to
involve different critical ranges of the
preoperative CEA levels.
The authors thank Ms S. Glock for excellent
technical assistance.
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